Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00424177
Status:
COMPLETED
Last Update Posted:
2013-07-30
First Post:
2007-01-17
Brief Title:
Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura REPEAT
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
An Open-label Repeat Dosing Study of Eltrombopag Olamine SB-497115-GR in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura ITP
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This open-label repeat dosing study TRA108057 will evaluate the efficacy safety and tolerability of eltrombopag when administered in a repeat cyclic dosing schedule The study will describe the effect of repeated 3 cycles intermittent dosing of eltrombopag on the pharmacodynamics and durability of eltrombopag response as measured by the peripheral platelet counts
For more information or to see if you qualify please visit httpwwwitpstudycomgov
For more information or to see if you qualify please visit httpwwwitpstudycomgov
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None